Brown Advisory Inc. cut its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 8.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,892 shares of the company’s stock after selling 1,437 shares during the period. Brown Advisory Inc.’s holdings in Catalent were worth $1,044,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Catalent by 3.9% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 98,422 shares of the company’s stock worth $4,430,000 after purchasing an additional 3,721 shares in the last quarter. Park Place Capital Corp increased its stake in shares of Catalent by 43.9% during the 1st quarter. Park Place Capital Corp now owns 1,294 shares of the company’s stock worth $85,000 after purchasing an additional 395 shares in the last quarter. Earnest Partners LLC increased its stake in shares of Catalent by 19.9% during the 4th quarter. Earnest Partners LLC now owns 2,685,136 shares of the company’s stock worth $120,858,000 after purchasing an additional 445,745 shares in the last quarter. Raymond James & Associates increased its stake in shares of Catalent by 1.9% during the 1st quarter. Raymond James & Associates now owns 198,962 shares of the company’s stock worth $13,074,000 after purchasing an additional 3,630 shares in the last quarter. Finally, Hunter Perkins Capital Management LLC increased its stake in shares of Catalent by 1.9% during the 1st quarter. Hunter Perkins Capital Management LLC now owns 71,175 shares of the company’s stock worth $4,677,000 after purchasing an additional 1,350 shares in the last quarter.
Catalent Stock Up 0.3 %
Shares of CTLT opened at $45.42 on Wednesday. The firm has a market cap of $8.19 billion, a PE ratio of 206.46, a price-to-earnings-growth ratio of 5.35 and a beta of 1.23. The company’s fifty day moving average is $44.96 and its two-hundred day moving average is $51.90. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $110.17. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91.
Wall Street Analysts Forecast Growth
CTLT has been the subject of a number of recent research reports. Wells Fargo & Company initiated coverage on shares of Catalent in a research note on Thursday, July 20th. They set an “equal weight” rating and a $43.00 price objective for the company. Robert W. Baird lifted their target price on shares of Catalent from $35.00 to $47.00 in a research note on Tuesday, June 13th. Barclays lifted their target price on shares of Catalent from $35.00 to $42.00 in a research note on Monday, June 12th. Bank of America lifted their target price on shares of Catalent from $28.00 to $33.00 in a research note on Tuesday, June 13th. Finally, TheStreet cut shares of Catalent from a “c” rating to a “d+” rating in a research note on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $56.92.
Check Out Our Latest Stock Analysis on CTLT
Insider Activity at Catalent
In related news, CEO Alessandro Maselli sold 1,485 shares of Catalent stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total transaction of $69,988.05. Following the transaction, the chief executive officer now owns 86,101 shares in the company, valued at approximately $4,057,940.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 1,889 shares of company stock worth $89,248. 0.58% of the stock is currently owned by corporate insiders.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More
- Five stocks we like better than Catalent
- How to Invest in Music Stocks
- On Holding Slips Into A More Comfortable Price PointÂ
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Growing Cannabis Stocks Ready To Bloom
- What is a Secondary Public Offering? What Investors Need to Know
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT – Free Report).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
